AbbVie is ending a decade-long partnership with Calico Life Sciences, an Alphabet-funded biotech company focused on aging research, and laying off chemists working on discovering new drugs.
The moves, detailed in internal emails sent Tuesday and viewed by STAT, come as the pharmaceutical giant is moving away from small-molecule drugs, which include pills, and investing more in injectable therapies and complex genetic medicines.
AbbVie did not immediately respond to a request for comment Wednesday.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
